Amarin appoints Jan van Heek

pharmafile | February 15, 2010 | Appointment | Research and Development, Sales and Marketing Amarin, appointment, research and development, sales and marketing 

Jan van Heek has joined Amarin’s board of directors of as a non-executive director and will also take on the role of chairman of the Dublin-based company’s audit committee.

His healthcare career spans more than 30 years in the healthcare industry and he is currently a principal and partner at advisory company BioPoint.

Prior to establishing BioPoint, Jan spent more than 18 years at Genzyme, most recently as senior advisor to the chief executive and senior management team.

Advertisement

He joined Genzyme in 1991 where, as executive vice president, he was largely responsible for establishing and building its worldwide therapeutics, surgical and genetic testing businesses.

“Jan van Heek has a wealth of industry experience derived from helping to build one of the world’s largest and most successful biotech companies,” commented Joseph Zakrzewski, executive chairman of Amarin. “We are very pleased he will bring this knowledge to support Amarin as we strive to create a valuable company focused on new products to improve the treatment of cardiovascular diseases.”

Prior to Genzyme, Jan held various management positions at Baxter Healthcare in Europe and the US.

Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025

The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy

Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months

TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …

The Gateway to Local Adoption Series

Latest content